Synthesis and antiproliferative activity of thiazolidine analogs for melanoma

Wei Li, Yan Lu, Zhao Wang, James T. Dalton, Duane Miller

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We have previously described 2-aryl-thiazolidine-4-carboxylic acid amides as a novel class of antiproliferative agents for prostate cancer. Screening these compounds with melanoma cell lines revealed that several of them have potent antiproliferative activity and selectivity against melanoma. To further improve the potency and selectivity, we synthesized a new series of analogs and tested them in two melanoma cell lines and fibroblast cells (negative controls). Comparison of anticancer effects of these compounds with a standard chemotherapeutic agent, sorafenib, showed that they are very effective in killing melanoma cells with low micromolar to nanomolar antiproliferative activity and provide us a new lead for developing potential drugs for melanoma.

Original languageEnglish (US)
Pages (from-to)4113-4117
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume17
Issue number15
DOIs
StatePublished - Aug 1 2007

Fingerprint

Thiazolidines
Melanoma
Cells
Fibroblasts
Amides
Screening
Cell Line
Prostatic Neoplasms
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. / Li, Wei; Lu, Yan; Wang, Zhao; Dalton, James T.; Miller, Duane.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 17, No. 15, 01.08.2007, p. 4113-4117.

Research output: Contribution to journalArticle

@article{2d0188d63253412d92a1205f4fe14529,
title = "Synthesis and antiproliferative activity of thiazolidine analogs for melanoma",
abstract = "We have previously described 2-aryl-thiazolidine-4-carboxylic acid amides as a novel class of antiproliferative agents for prostate cancer. Screening these compounds with melanoma cell lines revealed that several of them have potent antiproliferative activity and selectivity against melanoma. To further improve the potency and selectivity, we synthesized a new series of analogs and tested them in two melanoma cell lines and fibroblast cells (negative controls). Comparison of anticancer effects of these compounds with a standard chemotherapeutic agent, sorafenib, showed that they are very effective in killing melanoma cells with low micromolar to nanomolar antiproliferative activity and provide us a new lead for developing potential drugs for melanoma.",
author = "Wei Li and Yan Lu and Zhao Wang and Dalton, {James T.} and Duane Miller",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.bmcl.2007.05.059",
language = "English (US)",
volume = "17",
pages = "4113--4117",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Synthesis and antiproliferative activity of thiazolidine analogs for melanoma

AU - Li, Wei

AU - Lu, Yan

AU - Wang, Zhao

AU - Dalton, James T.

AU - Miller, Duane

PY - 2007/8/1

Y1 - 2007/8/1

N2 - We have previously described 2-aryl-thiazolidine-4-carboxylic acid amides as a novel class of antiproliferative agents for prostate cancer. Screening these compounds with melanoma cell lines revealed that several of them have potent antiproliferative activity and selectivity against melanoma. To further improve the potency and selectivity, we synthesized a new series of analogs and tested them in two melanoma cell lines and fibroblast cells (negative controls). Comparison of anticancer effects of these compounds with a standard chemotherapeutic agent, sorafenib, showed that they are very effective in killing melanoma cells with low micromolar to nanomolar antiproliferative activity and provide us a new lead for developing potential drugs for melanoma.

AB - We have previously described 2-aryl-thiazolidine-4-carboxylic acid amides as a novel class of antiproliferative agents for prostate cancer. Screening these compounds with melanoma cell lines revealed that several of them have potent antiproliferative activity and selectivity against melanoma. To further improve the potency and selectivity, we synthesized a new series of analogs and tested them in two melanoma cell lines and fibroblast cells (negative controls). Comparison of anticancer effects of these compounds with a standard chemotherapeutic agent, sorafenib, showed that they are very effective in killing melanoma cells with low micromolar to nanomolar antiproliferative activity and provide us a new lead for developing potential drugs for melanoma.

UR - http://www.scopus.com/inward/record.url?scp=34347373450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347373450&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2007.05.059

DO - 10.1016/j.bmcl.2007.05.059

M3 - Article

VL - 17

SP - 4113

EP - 4117

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 15

ER -